FDA Approves Liraglutide, With Warning, Caveats: The once-weekly GLP-1 receptor agonist is not indicated for first-line treatment of type 2 diabetes.

The Food and Drug Administration has approved liraglutide as a once-daily injection for the treatment of type 2 diabetes. But the endorsement came with significant caveats. The drug has a boxed warning about thyroid C-cell tumors observed in preclinical rodent studies, no permission for first-line use, and significant postmarketing requirements.